Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00149617
Status:
COMPLETED
Last Update Posted:
2015-10-09
First Post:
2005-09-06
Brief Title:
Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1
Sponsor:
Medical University of South Carolina
Organization:
Medical University of South Carolina
Study Overview
Official Title:
Career Training in Marijuana Dependence
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the effectiveness of a combination of buspirone and motivational interviewing therapy in the treatment of marijuana dependence
Detailed Description:
Marijuana dependence is one of the most common substance-related disorders in the United States Despite its prevalence there is a lack of clinical research addressing treatments for marijuana dependence Research has shown that marijuana abuse is associated with affective disorders This may be caused by repeated use for relief from anxiety The use of an anxiolytic agent a drug that relieves anxiety may help treat marijuana dependence Motivational enhancement therapy has been shown to reduce marijuana use Therefore it is likely that buspirone which is an anxiolytic agent combined with motivational enhancement therapy will prove beneficial in treating marijuana dependence This study will assess the effectiveness of a combination of buspirone and motivational interviewing in the treatment of marijuana dependence
This double-blind study will last a total of 16 weeks Participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks There will be one follow-up appointment 4 weeks post-intervention Baseline assessments will include a physical exam and urine and blood tests Study visits will occur weekly throughout treatment in order to monitor compliance assess adverse affects and obtain substance use data Mood assessment scales marijuana craving questionnaires and a withdrawal symptom checklist will be used to gather the data Urine drug screens will be collected weekly to test for marijuana use In addition to this the presence of opioids cocaine amphetamines and benzodiazepines will be tested at baseline Weeks 6 and 12 and at follow-up A 10-day supply of medication will be dispensed to participants each week Meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline Week 2 and Week 4 Participants perceived quality of life will be measured at baseline and Weeks 6 and 12 to determine the effect of buspirone
This double-blind study will last a total of 16 weeks Participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks There will be one follow-up appointment 4 weeks post-intervention Baseline assessments will include a physical exam and urine and blood tests Study visits will occur weekly throughout treatment in order to monitor compliance assess adverse affects and obtain substance use data Mood assessment scales marijuana craving questionnaires and a withdrawal symptom checklist will be used to gather the data Urine drug screens will be collected weekly to test for marijuana use In addition to this the presence of opioids cocaine amphetamines and benzodiazepines will be tested at baseline Weeks 6 and 12 and at follow-up A 10-day supply of medication will be dispensed to participants each week Meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline Week 2 and Week 4 Participants perceived quality of life will be measured at baseline and Weeks 6 and 12 to determine the effect of buspirone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| K23DA015440 | NIH | None | None |
| K23-15440-1 | None | None | None |
| DPMC | US NIH GrantContract | None | httpsreporternihgovquickSearchK23DA015440 |